Attenuation of iminodipropionitrile induced behavioral syndrome by sodium salicylate in rats.
Iminodipropionitrile (IDPN) produces irreversible behavioral abnormalities characterized by excitation with choreiform and circling movements (ECC) syndrome in rodents. Concomitant exposure to drugs or environmental chemicals has been shown to alter IDPN-induced neurobehavioral toxicity. This investigation was undertaken to study the effect of sodium salicylate (SS) on IDPN-induced behavioral abnormalities in rats. The animals were exposed to IDPN (100 mg/kg ip) daily for 8 days. SS was administered daily 30 min before IDPN in the doses of 50, 100 and 200 mg/kg ip for 12 days. The animals were observed for neurobehavioral abnormalities including dyskinetic head movements, circling, tail hanging, air righting reflex and contact inhibition of the righting reflex. Horizontal and vertical locomotor activities and forelimbs grip strength were also measured. After behavioral studies, the animals were sacrificed, and the cerebrum and temporal bones were collected for glutathione analysis and inner ear histopathology, respectively. The onset of ECC syndrome was observed on Day 9 in the IDPN-alone group with 100% incidence on Day 12. Cotreatment with salicylate dose-dependently delayed the onset time and significantly attenuated the incidence and severity of IDPN-induced neurobehavioral signs. IDPN alone significantly increased horizontal motor activity and reduced vertical motor activity and forelimbs grip strength; these effect were significantly reversed by salicylate treatment. Treatment with salicylate also attenuated IDPN-induced depletion of GSH in the cerebrum, suggesting its free radical scavenging property.
Tariq
Mohammad
M
Neuroscience Research Group, Armed Forces Hospital, PO Box 7897 (W-912), 11159, Riyadh, Saudi Arabia. yasom70@hotmail.com
Khan
Haseeb Ahmad
HA
Al Moutaery
Khalaf
K
Al Deeb
Saleh
S
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001923:Brain Chemistry / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004409:Dyskinesia, Drug-Induced / Q000523:psychology; D007758:Ear, Inner / Q000187:drug effects / Q000473:pathology; D005260:Female; D005978:Glutathione / Q000378:metabolism; D018737:Hand Strength / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects; D020258:Neurotoxicity Syndromes / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology*; D009570:Nitriles / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012980:Sodium Salicylate / Q000494:pharmacology*
D016861:Cyclooxygenase Inhibitors; D009570:Nitriles; C008110:3,3'-iminodipropionitrile; D005978:Glutathione; D012980:Sodium Salicylate